Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

179.18 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 Next >
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside ↗
Via Stocktwits
Ralph Lauren Unveils Three-Year Outlook – Here Are The Key Points ↗
Via Stocktwits
News headline image
Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot ↗
UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store... 
Via Stocktwits
Caleres Draws ‘Less Risk’ Rating From Telsey, Retail Chatter Surges 700% ↗
Via Stocktwits
News headline image
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3 ↗
The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday. 
Via Stocktwits
News headline image
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More ↗
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 
Via Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
Via Stocktwits
Lyft Has A ‘Steady Path Forward’ According To UBS: Retail Thinks Stock Is Undervalued ↗
Via Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming ↗
Via Stocktwits
News headline image
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
News headline image
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity ↗
Via Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price ↗
Via Stocktwits
News headline image
Hims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent Expires ↗
The telehealth company stated that its entry to Canada will come as generic semaglutide hits the market for the first time. 
Via Stocktwits
Topics Intellectual Property
News headline image
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity ↗
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. 
Via Stocktwits
Topics Government
News headline image
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated ↗
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous... 
Via Stocktwits
News headline image
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report ↗
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that... 
Via Stocktwits
News headline image
5 Surprising Vanguard ETFs That Could Beat the Market ↗
Not all Vanguard ETFs are the index funds you're probably familiar with. 
Via The Motley Fool
Topics ETFs
News headline image
After Beating the S&P 500 in 2024, This Vanguard Growth ETF Is Already Up Over 6% in 2025 ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Don't Miss This Actively Managed Vanguard ETF That Could Supercharge Your Returns ↗
This Vanguard fund could help diversify your ETF portfolio. 
Via The Motley Fool
Topics ETFs
News headline image
Vanguard ETFs: An Overview ↗
This ETF family is renowned for high capital returns, low expenses, and upholding management practices that prioritize shareholder interests. 
Via The Motley Fool
Topics ETFs
News headline image
This Is the Perfect Vanguard ETF for Investors With a Fear of Missing Out on the Market's Biggest Winners ↗
Don't fear: There's an ETF that will ensure you don't miss out on any high-flying stocks. 
Via The Motley Fool
Topics ETFs
News headline image
Like the "Magnificent Seven" Stocks? You'll Love This Vanguard ETF. ↗
This Vanguard ETF is a great way to invest in momentum stocks. 
Via The Motley Fool
Topics ETFs
News headline image
ETF Battles: Looking For The Best Momentum Stock ETF? It's MTUM vs. MTMM vs. JMOM vs. VFMO! ↗
In this episode of ETF Battles, Ron DeLegge @ETFguide referees an audience requested quadruple-header duel between 4 momentum focused stock ETFs. 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.